Nanjing Minova Pharmaceutical

Lead program MI-078 (small molecule for postpartum depression) completed Phase II trials, demonstrating achievement of primary efficacy endpoint with statistically superior efficacy to placebo; rapid onset of action reported (effective within 3 days of oral administration); regarded as first domestic Class 1 innovative drug for postpartum depression in China. Rongzhi® (deoxycholic acid, DCA injection) approved/commercialized for lipolysis (localized obesity/fat reduction) as first compliant product in China in this space; actively marketed nationally. Dermatology pipeline (alopecia, photoaging, cicatrix) progressing with multiple assets in early clinical/preclinical stages. Nanjing Minova Pharmaceutical/Minowei/Minovay is a rapidly growing Chinese pharma/biotech innovator developing small molecule drugs targeting mental health (postpartum depression), dermatology (alopecia, skin aging), and metabolic indications (lipolysis). Its programs include both clinical-stage and commercial products (Rongzhi®), with the company achieving notable regulatory and clinical milestones in under five years of existence.